SCHEMBL715736

SCHEMBL715736

Cc1cccc2cc([C@H](C)N)c(N3CCCC3)nc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.59
L3MBTL1 Q9Y468 4/20 0.59
TSHR P16473 4/20 0.59
CASP1 P29466 4/20 0.59
CASP7 P55210 4/20 0.59
KDM4E B2RXH2 8/20 0.47
ALDH1A1 P00352 5/20 0.47
USP2 O75604 2/20 0.47
CLK1 P49759 1/20 0.47
PIK3CD O00329 6/20 0.47
TDP1 Q9NUW8 3/20 0.47
GAA P10253 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.44
HSD17B10 Q99714 4/20 0.41
MAPT P10636 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL845236 1.00 ALOX15 (0.59) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL715249 0.85 HPGD (0.43) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL717258 0.84 PIK3CD (0.53) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL717259 0.84 PIK3CD (0.53) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL17530798 0.83 L3MBTL1 (0.52) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL715528 0.81 MAPT (0.47) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL715529 0.81 MAPT (0.47) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL716475 0.80 PIK3CD (0.40) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL15875825 0.80 L3MBTL1 (0.54) ALOX15L3MBTL1TSHRCASP1CASP7
SCHEMBL715662 0.79 PIK3CD (0.55) ALOX15L3MBTL1TSHRCASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 ALOX15 1365/4885L3MBTL1 2277/4885TSHR 931/4885
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors PI4KA, PDPK1, PIK3CA ALOX15 1348/4885L3MBTL1 4171/4885TSHR 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.